Cannabinoid action depends on phosphorylation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa at the protein kinase A site in striatal projection neurons
about
Integrated signaling in heterodimers and receptor mosaics of different types of GPCRs of the forebrain: relevance for schizophreniaThe endocannabinoid system as an emerging target of pharmacotherapyLooking for the role of cannabinoid receptor heteromers in striatal functionAdenosine A2A receptors and basal ganglia physiologyAdenosine A2A receptors in ventral striatum, hypothalamus and nociceptive circuitry implications for drug addiction, sleep and painRegulation of asymmetrical cytokinesis by cAMP during meiosis I in mouse oocytesAdenosine-cannabinoid receptor interactions. Implications for striatal functionInternational Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂Adenosine A(2A) receptors in psychopharmacology: modulators of behavior, mood and cognition.Decreased dopamine brain reactivity in marijuana abusers is associated with negative emotionality and addiction severityNeuroprotective potential of CB1 receptor agonists in an in vitro model of Huntington's disease.Delta FosB and AP-1-mediated transcription modulate cannabinoid CB₁ receptor signaling and desensitization in striatal and limbic brain regions.Theoretical considerations on the topological organization of receptor mosaicsIn vivo manganese exposure modulates Erk, Akt and Darpp-32 in the striatum of developing rats, and impairs their motor function.The CB1 cannabinoid receptor agonist reduces L-DOPA-induced motor fluctuation and ERK1/2 phosphorylation in 6-OHDA-lesioned ratsCB1-independent inhibition of dopamine transporter activity by cannabinoids in mouse dorsal striatum.Protein kinases and addiction.Reinforcing and neurochemical effects of cannabinoid CB1 receptor agonists, but not cocaine, are altered by an adenosine A2A receptor antagonist.Adenosine A(2A) Receptors and A(2A) Receptor Heteromers as Key Players in Striatal FunctionAdenosine A₂A receptors in striatal glutamatergic terminals and GABAergic neurons oppositely modulate psychostimulant action and DARPP-32 phosphorylation.Pharmacological evidence for different populations of postsynaptic adenosine A2A receptors in the rat striatumCB(1) cannabinoid receptors and their associated proteins.Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.Opposite function of dopamine D1 and N-methyl-D-aspartate receptors in striatal cannabinoid-mediated signaling.Behavioral and neurochemical changes in mesostriatal dopaminergic regions of the rat after chronic administration of the cannabinoid receptor agonist WIN55,212-2.The cannabinoid agonist WIN55212-2 decreases L-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated ratsRole of Dopamine Type 1 Receptors and Dopamine- and cAMP-Regulated Phosphoprotein Mr 32 kDa in Δ9-Tetrahydrocannabinol-Mediated Induction of ΔFosB in the Mouse ForebrainBiological Significance of GPCR Heteromerization in the Neuro-Endocrine SystemNew insights on endocannabinoid transmission in psychomotor disorders.From prediction error to psychosis: ketamine as a pharmacological model of delusions.Is DARPP-32 a potential therapeutic target?Tuning and fine-tuning of synapses with adenosine.Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.G-protein-coupled receptor heteromers as key players in the molecular architecture of the central nervous system.Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia.Crosstalk between dopamine D₂ receptors and cannabinoid CB₁ receptors regulates CNR1 promoter activity via ERK1/2 signaling.Disruption of IFN-gamma- mediated antiviral activity in neurons: the role of cannabinoidsCannabinoids in Parkinson's DiseaseΔ9-Tetrahydrocannabinol Experience Influences ΔFosB and Downstream Gene Expression in Prefrontal Cortex.An integrated view on the role of receptor mosaics at perisynaptic level: focus on adenosine A(2A), dopamine D(2), cannabinoid CB(1), and metabotropic glutamate mGlu(5) receptors.
P2860
Q24632803-7B2080ED-BE40-4E2C-9328-CE61221FE412Q24648473-3AE66DF2-2E81-41CD-A130-261F8FEFFABAQ24658338-7DA85D0D-D5EB-4D94-9B27-6CB9CF658CACQ24669783-B2BFAD1E-0F15-4216-A40C-E57EC392067CQ24676705-4862EFE4-2DEB-4DF5-882B-FB8378C1005EQ27310328-C11B6CE3-3D0A-4259-A057-BCF786A8E84AQ28286488-8F0D49D5-B500-40F3-BBDE-F50B9D7947BBQ28298445-13C89F13-7876-4800-8709-4D536C9F98D7Q30482913-8664145C-DA28-4BC1-8F4E-3D4DDBBD4C25Q34002281-25968C7B-D79D-485E-874F-E5BD51C1858CQ34098292-58E6950F-EA76-46EB-9BBA-EBF2DB0FB42DQ34170521-DA7C5263-7418-4AF9-965F-C5C455E2B476Q34171499-1A6A1F50-190C-4B49-933B-004AF6FEB1C7Q34200391-A94458A6-3246-47EF-8857-4509D37725F8Q34482483-55E4FC25-CCFD-4B93-920D-3FF1712E47EBQ34605794-753231C6-1E2B-4254-9F99-194EC942779CQ34630295-1C189056-8A78-45C4-8BE4-DE9E5B27C862Q35046370-CD90DE47-FF14-45FD-B541-EFAB69345C8DQ35056410-A592EB39-88CF-47E2-8DFB-26F934801559Q35060382-6A85E01A-6C56-4C0C-BB52-817D44098236Q35166968-71D614DA-CBCE-440E-8F0B-D0777450A60BQ35232109-F627C89B-0EE1-4C4A-8543-B06C0B7596A6Q35489240-9998B8E4-0D3D-4C8D-AF8F-B12DF92B2BEBQ35575588-E989929A-1B52-4BA7-849F-107F89D46910Q35626928-82F4B0A9-0762-4B09-8808-FD436C63F32BQ35740152-BBE3B50D-FB21-451C-9D60-3DF08FB4BD6CQ35962060-C516E38A-AE98-43DB-8214-7FB98FDDF59CQ35971498-771E538D-FDBB-4085-8A5D-FEC6CF13156CQ36074595-A19C3931-B9DA-4BA8-9959-1868D65494F6Q36860032-B083E496-B375-46C3-8826-8D9B7D5A1FF5Q37004761-06C0F737-6686-4406-A218-48449B042375Q37700201-943DE7A1-CA1E-4FB8-816D-0CF216CF2888Q37924629-27331461-2531-43C1-A151-DD8253706FA2Q38210280-F928BA66-3E62-4EE1-A9F8-C829938C870DQ38522769-F591E3BE-6721-45E7-A69E-3DAAE406676CQ39109270-599D20C1-4DA7-4A5E-A852-88F4C5917CADQ39969705-532D7D20-5A55-4A66-B7E8-2BB2CB2F621DQ42258332-A6B1EDC1-9313-4F91-96FA-5223102C8A87Q42713642-41C7656D-10EB-4FEF-870B-1685F11CE5B5Q43044221-7DF59F6A-DAC8-4D6E-84E1-E450B85BDCBE
P2860
Cannabinoid action depends on phosphorylation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa at the protein kinase A site in striatal projection neurons
description
2005 nî lūn-bûn
@nan
2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Cannabinoid action depends on ...... in striatal projection neurons
@ast
Cannabinoid action depends on ...... in striatal projection neurons
@en
Cannabinoid action depends on ...... in striatal projection neurons
@nl
type
label
Cannabinoid action depends on ...... in striatal projection neurons
@ast
Cannabinoid action depends on ...... in striatal projection neurons
@en
Cannabinoid action depends on ...... in striatal projection neurons
@nl
prefLabel
Cannabinoid action depends on ...... in striatal projection neurons
@ast
Cannabinoid action depends on ...... in striatal projection neurons
@en
Cannabinoid action depends on ...... in striatal projection neurons
@nl
P2093
P921
P1476
Cannabinoid action depends on ...... in striatal projection neurons
@en
P2093
Allen A Fienberg
Anders Borgkvist
Bertil B Fredholm
Cecilia Dominguez
Emiliana Borrelli
Gilberto Fisone
Laura Pozzi
Mikael Andersson
Paul Greengard
Per Svenningsson
P304
P356
10.1523/JNEUROSCI.1289-05.2005
P407
P577
2005-09-01T00:00:00Z